Emerging therapeutic targets and strategies in Crohn’s disease

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 6, 2016, Pages 735-744

  Furfaro, Federica ^a,b   Fiorino, Gionata ^a   Allocca, Mariangela ^a   Gilardi, Daniela ^a   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

anti adhesion molecules; anti cytokine; biologics; Crohn s disease; small molecules

Indexed keywords

AJM 300; ALICAFORSEN; AMGEN 181; AMISELIMOD; EFALIZUMAB; ELDELUMAB; ETROLIZUMAB; FINGOLIMOD; HMPL 004; LAQUINIMOD; MASITINIB; MEDI 2070; METHOTREXATE; MONGERSEN; MONOCLONAL ANTIBODY; NATALIZUMAB; PF 00547659; PF 04236921; PLACEBO; PREDNISOLONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 10; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB; VERCIRNON; ANTIINFLAMMATORY AGENT; AUTACOID; CELL ADHESION MOLECULE; GASTROINTESTINAL AGENT;

ANTIINFLAMMATORY ACTIVITY; CROHN DISEASE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; FECAL MICROBIOTA TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE MIGRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; IMMUNOLOGY; INTESTINE MUCOSA; MOLECULARLY TARGETED THERAPY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL ADHESION MOLECULES; CHEMOTAXIS, LEUKOCYTE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84958523428     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1142372     Document Type: Review

References (103)

1. C.Abraham, J.H.Cho Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
2. H.M.Van Dullemen, S.J.Van Deventer, D.W.Hommes, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109(1):129–135.
3. B.W.Behm, S.J.Bickston. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;23(1):CD006893.
4. W.Moon, L.Pestana, B.Becker, et al. Efficacy and safety of certolizumab pegol for Crohn’s disease in clinical practice. Aliment Pharmacol Ther. 2015;42(4):428–440.
5. W.J.Sandborn, G.Y.Melmed, D.P.McGovern, et al. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn’s disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015;42(3):330–342.
6. L.Peyrin-Biroulet. Managing inflammatory bowel disease in the biologics era: treating beyond symptoms is not sufficient. Rev Prat. 2014;64(9):1207–1209.
7. S.Danese, G.Fiorino, C.Fernandes, et al. Catching the therapeutic window of opportunity in early Crohn’s disease. Curr Drug Targets. 2014;15(11):1056–1063.
8. M.J.Waldner, M.F.Neurath. Novel cytokine-targeted therapies and intestinal inflammation. Curr Opin Pharmacol. 2009;9(6):702–707.
9. S.Ben-Horin, U.Kopylov, Y.Chowers. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30.
10. P.M.Irving. Can we get more from our current treatments? Best Pract Res Clin Gastroenterol. 2014;28(3):451–463.
11. S.Danese, G.Fiorino, W.Reinisch. Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011;34(1):1–10.
12. U.Kopylov, G.J.Mantzaris, K.H.Katsanos, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther. 2011;33(3):349–357.
13. M.Cesarini, K.Katsanos, K.Papamichael, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46(2):135–139.
14. N.Vande Casteele, G.Compernolle, V.Ballet, et al. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohns Colitis. 2012;6(Suppl 1):S6.
15. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64(10):1539–1545.•• The TAXIT study.
16. C.Steenholdt, J.Brynskov, O.O.Thomsen, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–927.• First RCT that demonstrate the importance of individualized therapy in CD.
17. C.Steenholdt, J.Brynskov, O.O.Thomsen, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab. Dig Dis Sci. 2015;60(9):2762–2770.
18. P.Marits, L.Landucci, U.Sundin, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis. 2014;8(8):881–889.
19. M.Bortlik, D.Duricova, K.Malickova, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis. 2013;7(9):736–743.
20. N.Vande Casteele, M.Ferrante, G.Van Assche, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329. e1323.
21. A.J.Yarur, A.Jain, D.A.Sussman, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–255.
22. A.Vatansever, C.Cekic, N.Ekinci, et al. Effects of mucosal TNF-alpha levels on treatment response in Crohn’s disease patients receiving anti-TNF treatment. Hepatogastroenterology. 2014;61(136):2277–2282.
23. A.Amiot, L.Peyrin-Biroulet. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8(2):66–82.
24. B.E.Sands. New drug on the horizon for IBD. Dig Dis. 2014;32(Suppl 1):74–81.
25. T.A.Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301–314.
26. K.Ley. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9(6):263–268.
27. K.O.Arseneau, F.Cominelli. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther. 2015;97(1):22–28.
28. M.Cesarini, G.Fiorino. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease–an update. Expert Rev Clin Immunol. 2013;9(4):301–306.
29. F.H.Gordon, C.W.Lai, M.I.Hamilton, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology. 2001;121(2):268–274.
30. S.Ghosh, E.Goldin, F.H.Gordon, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348(1):24–32.
31. W.J.Sandborn, J.F.Colombel, R.Enns, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–1925.• First trial on the efficacy of natalizumab in Crohn’s disease.
32. S.R.Targan, B.G.Feagan, R.N.Fedorak, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–1683.• Large randomized trial showing the efficacy of natalizumab on inducing and maintaining remission in Crohn’s disease.
33. G.Bloomgren, S.Richman, C.Hotermans, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
34. D.Soler, T.Chapman, L.Yang, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.• Study that clearly explains the mechanism of action of vedolizumab.
35. W.J.Sandborn, B.G.Feagan, P.Rutgeerts, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.•• GEMINI 2 trial to evaluate the efficacy of vedolizumab in CD.
36. B.E.Sands, B.G.Feagan, P.Rutgeerts, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627. e613.
37. L.Hahn, A.Beggs, K.Wahaib, et al. Vedolizumab: an integrin-receptor antagonist for treatment of Crohn’s disease and ulcerative colitis. Am J Health Syst Pharm. 2015;72(15):1271–1278.
38. R.M.Poole. Vedolizumab: first global approval. Drugs. 2014;74(11):1293–1303.• Approvation of vedolizumab.
39. G.Fiorino, S.Danese. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa. Gastroenterology. 2014;147(6):1433–1435.
40. S.Vermeire, S.O’Byrne, M.Keir, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–318.
41. P.J.Rutgeerts, R.N.Fedorak, D.W.Hommes, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013;62(8):1122–1130.
42. Open-label extension and safety study for patients with Crohn’s disease previously enrolled in the etrolizumab phase III study GA29144. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
43. A study of the safety and efficacy of etrolizumab in patients with moderately to severely active Crohn’s disease. ethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
44. S.Vermeire, S.Ghosh, J.Panes, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60:1068–1075.
45. J.Panes. What is disease progression in Crohn’s disease and how can it be measured? J Crohns Colitis. 2015;9(8):599–600.
46. Evaluate PF-00547659 on cerebrospinal fluid lymphocytes in volunteers with Crohn’s disease or ulcerative colitis who failed or did not tolerate anti-TNFs (TOSCA). Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
47. A study to monitor long-term treatment with PF-00547659 (OPERA II). Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
48. Study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 181. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
49. H.Li, K.Kock, J.A.Wisler, et al. Prediction of clinical pharmacokinetics of AMG 181, a human anti-alpha 4 beta 7 monoclonal antibody for treating inflammatory bowel diseases. Pharmacol Res Perspect. 2015;3(1):e00098.
50. W.J.Pan, K.Kock, W.A.Rees, et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol. 2014;78(6):1315–1333.
51. W.J.Pan, H.Hsu, W.A.Rees, et al. Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013;169(1):51–68.
52. AMG 181 in subjects with moderate to severe Crohn’s disease. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
53. M.Löwenberg, G.D’Haens. Next-generation therapeutics for IBD. Curr Gastroenterol Rep. 2015;17(6):21.
54. Induction and maintenance study of BMS-936557 in patients with moderate to severely active Crohn’s disease. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
55. L.Mayer, W.J.Sandborn, Y.Stepanov, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63(3):442–450.
56. S.Schreiber, S.Nikolaus, H.Malchow, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease. Gastroenterology. 2001;120:1339–1346.
57. B.R.Yacyshyn, W.Chey, M.K.Wedel, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inibitor of intracellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin Gastroenterol Hepatol. 2007;5(2):215–220.
58. B.R.Yacyshyn, W.Y.Chey, J.Goff, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut. 2002;51(1):30–36.
59. S.Thomas, D.C.Baumgart. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology. 2012;20(1):1–18.
60. S.Keshav, T.Vanasek, Y.Niv, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn’s disease. PLoS One. 2013;8(3):e60094.
61. D.G.James, D.H.Seo, J.Chen, et al. Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn’s disease: an open-label pilot study. Dig Dis Sci. 2011;56(6):1806–1810.
62. I.Marafini, E.Angelucci, F.Pallone, et al. The IL-12/23/STAT axis as a therapeutic target in inflammatory bowel disease: mechanisms and evidence in man. Dig Dis. 2015;33(Suppl 1):113–119.
63. G.Fiorino, P.D.Omodei. Psoriasis and inflammatory bowel disease: two sides of the same coin? J Crohns Colitis. 2015;9(9):697–698.
64. W.J.Sandborn, B.G.Feagan, R.N.Fedorak, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–1141.•• RCT that demonstrates effectiveness of Ustekinumab for treatment of CD.
65. W.J.Sandborn, C.Gasink, L.L.Gao, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–1528.
66. A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn’s disease (IM-UNITI). Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
67. Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn’s disease. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
68. Efficacy, safety and pharmacokinetics of BI 655066 in patients with active, moderate-to-severe Crohn’s disease. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
69. M.Allocca, M.Jovani, G.Fiorino, et al. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Curr Drug Targets. 2013;14(12):1508–1521.
70. A study to assess the efficacy and safety of PF-04236921 in subjects with Crohn’s disease who failed anti-TNF therapy (ANDANTE). Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
71. A.Di Sabatino, C.L.Jackson, K.M.Pickard, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut. 2009;58(6):777–789.
72. G.Monteleone, M.F.Neurath, S.Ardizzone, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–1113.•• Phase II study that demonstrates effectiveness of anti SMAD for treatment of CD.
73. B.S.Boland, W.J.Sandborn, J.T.Chang. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):603–617.
74. I.Bravata, G.Fiorino, M.Allocca, et al. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(1):113–120.
75. W.J.Sandborn, S.Ghosh, J.Panes, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624.
76. W.J.Sandborn, S.Ghosh, J.Panes, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485–1493. e1482.
77. M.Stasiolek, R.A.Linker, L.Hayardeny, et al. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study. Immun Inflamm Dis. 2015;3(2):45–55.
78. G.Comi, D.Jeffery, L.Kappos, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000–1009.
79. G.D’Haens, W.J.Sandborn, J.F.Colombel, et al. A phase II study of laquinimod in Crohn’s disease. Gut. 2015;64(8):1227–1235.
80. R.N.Fedorak, A.Gangl, C.O.Elson, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology. 2000;119(6):1473–1482.
81. J.Tebib, X.Mariette, P.Bourgeois, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther. 2009;11(3):R95.
82. J.Dong, H.Wang, G.Wu, et al. Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice. Clin Exp Immunol. 2014;177(1):94–101.
83. Safety and efficacy of MT-1303 in subjects with moderate to severe active Crohn’s disease. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
84. Extension study of MT-1303 in subjects with Crohn’s disease. Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
85. P.Bourlioux. Current view on gut microbiota. Ann Pharm Fr. 2014;72(1):15–21.
86. B.Cui, Q.Feng, H.Wang, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30(1):51–58.
87. A.I.Flores, G.J.Gomez-Gomez, A.Masedo-Gonzalez, et al. Stem cell therapy in inflammatory bowel disease: a promising therapeutic strategy? World J Stem Cells. 2015;7(2):343–351.
88. Study evaluating ovasave, an autologous cell therapy, in patients with active Crohn’s disease (CATS29). Bethesda (MA): U.S. National Institutes of Health; 2015. Available from: www.clinicaltrials.gov
89. R.K.Burt, R.M.Craig, F.Milanetti, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010;116(26):6123–6132.
90. Y.Oyama, R.M.Craig, A.E.Traynor, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology. 2005;128(3):552–563.
91. C.J.Hawkey, M.Allez, M.M.Clark, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA. 2015;314(23):2524–2534.
92. G.Y.Melmed, W.M.Pandak, K.Casey, et al. Human placenta-derived cells (PDA-001) for the treatment of moderate-to-severe Crohn’s disease: a phase 1b/2a study. Inflamm Bowel Dis. 2015;21(8):1809–1816.
93. M.Duijvestein, A.C.Vos, H.Roelofs, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59(12):1662–1669.
94. F.de la Portilla, F.Alba, D.Garcia-Olmo, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313–323.
95. M.R.Irhimeh, J.Cooney. Management of inflammatory bowel disease using stem cell therapy. Curr Stem Cell Res Ther. 2016;11(1):72–77.
96. M.Mutalib, O.Borrelli, S.Blackstock, et al. The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children. J Crohns Colitis. 2014;8(12):1730–1734.
97. S.Danese, J.Panés. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014;147(5):981–989.
98. R.Khanna, J.C.Preiss, J.MacDonald, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;5:CD007572.
99. Y.Leung, R.Panaccione. Update on ustekinumab for the treatment of Crohn’s disease. Gastroenterol Clin North Am. 2014;43(3):619–630.
100. R.Khanna, B.G.Feagan. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5(8):803–815.
101. C.Tillack, L.M.Ehmann, M.Friedrich, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–577.
102. G.Fiorino, C.Bonifacio, M.Allocca, et al. Bowel damage as assessed by the Lemann Index is reversible on anti-TNF therapy for Crohn’s disease. J Crohns Colitis. 2015;9(8):633–639.• The reversibility of Lemann Index during anti-TNF therapy.
103. J.F.Colombel, W.J.Sandborn, W.Reinisch, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395.